Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25532258 | 0.96 | LMNA (0.48) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL25532256 | 0.88 | LMNA (0.47) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL7841236 | 0.86 | MEN1 (0.53) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL4861409 | 0.85 | CTSL (0.53) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL3647693 | 0.85 | CTSL (0.53) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL4870701 | 0.84 | LMNA (0.54) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL10152341 | 0.83 | CTSL (0.51) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL6247146 | 0.82 | CTSL (0.51) | CTSLCTSBCTSSALDH1A1LMNA | |
| SCHEMBL16839634 | 0.82 | SMN1; SMN2 (0.50) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL1756761 | 0.82 | LMNA (0.53) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | CTSL 1276/4885CTSB 750/4885CTSS 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.